Cargando…
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations
PURPOSE: To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib + durvalumab, O + D) in patients with advanced solid, predominantly rare cancers harbouring homologous recombination repair (HRR) defects. PATIENTS AND METHODS: In total, 48 patients were treated with O + D, 16 wit...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403555/ https://www.ncbi.nlm.nih.gov/pubmed/37365284 http://dx.doi.org/10.1038/s41416-023-02311-0 |
_version_ | 1785085093772001280 |
---|---|
author | Thavaneswaran, Subotheni Kansara, Maya Lin, Frank Espinoza, David Grady, John P. Lee, Chee Khoon Ballinger, Mandy L. Sebastian, Lucille Corpuz, Theresa Qiu, Min Ru Mundra, Piyushkumar Bailey, Charles G. Schmitz, Ulf Simes, John Joshua, Anthony M. Thomas, David M. |
author_facet | Thavaneswaran, Subotheni Kansara, Maya Lin, Frank Espinoza, David Grady, John P. Lee, Chee Khoon Ballinger, Mandy L. Sebastian, Lucille Corpuz, Theresa Qiu, Min Ru Mundra, Piyushkumar Bailey, Charles G. Schmitz, Ulf Simes, John Joshua, Anthony M. Thomas, David M. |
author_sort | Thavaneswaran, Subotheni |
collection | PubMed |
description | PURPOSE: To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib + durvalumab, O + D) in patients with advanced solid, predominantly rare cancers harbouring homologous recombination repair (HRR) defects. PATIENTS AND METHODS: In total, 48 patients were treated with O + D, 16 with BRCA1/2 alterations (group 1) and 32 with other select HRR alterations (group 2). Overall, 32 (66%) patients had rare or less common cancers. The primary objective of this single-arm Phase II trial was a progression-free survival rate at 6 months (PFS6). Post hoc exploratory analyses were conducted on archival tumour tissue and serial bloods. RESULTS: The PFS6 rate was 35% and 38% with durable objective tumour responses (OTR) in 3(19%) and 3(9%) in groups 1 and 2, respectively. Rare cancers achieving an OTR included cholangiocarcinoma, perivascular epithelioid cell (PEComa), neuroendocrine, gallbladder and endometrial cancer. O + D was safe, with five serious adverse events related to the study drug(s) in 3 (6%) patients. A higher proportion of CD38 high B cells in the blood and higher CD40 expression in tumour was prognostic of survival. CONCLUSIONS: O + D demonstrated no new toxicity concerns and yielded a clinically meaningful PFS6 rate and durable OTRs across several cancers with HRR defects, including rare cancers. |
format | Online Article Text |
id | pubmed-10403555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-104035552023-08-06 A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations Thavaneswaran, Subotheni Kansara, Maya Lin, Frank Espinoza, David Grady, John P. Lee, Chee Khoon Ballinger, Mandy L. Sebastian, Lucille Corpuz, Theresa Qiu, Min Ru Mundra, Piyushkumar Bailey, Charles G. Schmitz, Ulf Simes, John Joshua, Anthony M. Thomas, David M. Br J Cancer Article PURPOSE: To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib + durvalumab, O + D) in patients with advanced solid, predominantly rare cancers harbouring homologous recombination repair (HRR) defects. PATIENTS AND METHODS: In total, 48 patients were treated with O + D, 16 with BRCA1/2 alterations (group 1) and 32 with other select HRR alterations (group 2). Overall, 32 (66%) patients had rare or less common cancers. The primary objective of this single-arm Phase II trial was a progression-free survival rate at 6 months (PFS6). Post hoc exploratory analyses were conducted on archival tumour tissue and serial bloods. RESULTS: The PFS6 rate was 35% and 38% with durable objective tumour responses (OTR) in 3(19%) and 3(9%) in groups 1 and 2, respectively. Rare cancers achieving an OTR included cholangiocarcinoma, perivascular epithelioid cell (PEComa), neuroendocrine, gallbladder and endometrial cancer. O + D was safe, with five serious adverse events related to the study drug(s) in 3 (6%) patients. A higher proportion of CD38 high B cells in the blood and higher CD40 expression in tumour was prognostic of survival. CONCLUSIONS: O + D demonstrated no new toxicity concerns and yielded a clinically meaningful PFS6 rate and durable OTRs across several cancers with HRR defects, including rare cancers. Nature Publishing Group UK 2023-06-26 2023-08-24 /pmc/articles/PMC10403555/ /pubmed/37365284 http://dx.doi.org/10.1038/s41416-023-02311-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Thavaneswaran, Subotheni Kansara, Maya Lin, Frank Espinoza, David Grady, John P. Lee, Chee Khoon Ballinger, Mandy L. Sebastian, Lucille Corpuz, Theresa Qiu, Min Ru Mundra, Piyushkumar Bailey, Charles G. Schmitz, Ulf Simes, John Joshua, Anthony M. Thomas, David M. A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations |
title | A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations |
title_full | A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations |
title_fullStr | A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations |
title_full_unstemmed | A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations |
title_short | A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations |
title_sort | signal-seeking phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403555/ https://www.ncbi.nlm.nih.gov/pubmed/37365284 http://dx.doi.org/10.1038/s41416-023-02311-0 |
work_keys_str_mv | AT thavaneswaransubotheni asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT kansaramaya asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT linfrank asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT espinozadavid asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT gradyjohnp asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT leecheekhoon asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT ballingermandyl asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT sebastianlucille asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT corpuztheresa asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT qiuminru asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT mundrapiyushkumar asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT baileycharlesg asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT schmitzulf asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT simesjohn asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT joshuaanthonym asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT thomasdavidm asignalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT thavaneswaransubotheni signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT kansaramaya signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT linfrank signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT espinozadavid signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT gradyjohnp signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT leecheekhoon signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT ballingermandyl signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT sebastianlucille signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT corpuztheresa signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT qiuminru signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT mundrapiyushkumar signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT baileycharlesg signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT schmitzulf signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT simesjohn signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT joshuaanthonym signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations AT thomasdavidm signalseekingphase2studyofolaparibanddurvalumabinadvancedsolidcancerswithhomologousrecombinationrepairgenealterations |